From Ambulance to Ward: What the Clinical Record Told the Sturgess Inquiry

The clinical record rarely arrives in a courtroom as a single document. At the Dawn Sturgess Inquiry it has come forward in fragments: a call log timed to the minute, a paramedic's contemporaneous notes, an observation chart, a referral email, a handwritten entry in a hospital file. Read together, they describe a patient journey. Read critically, they describe something else as well — the points at which a system recognised, or failed to recognise, an unusual presentation of harm.

This article concerns the clinical evidence rather than the environmental and decontamination material that has been considered elsewhere. Its purpose is to set out what the record appears to have established about the recognition and treatment of novichok exposure, and to identify the questions that remain live as the Inquiry's findings are awaited in 2026.

The first link in the chain

The pre-hospital phase has attracted attention less for what was done than for what was known at the time it was done. Evidence about the initial emergency response turns on the information available to responders: what was reported by the caller, what symptoms were observed on arrival, and what the working assumption was as clinicians began their assessment.

What the Inquiry has heard, in substance, is a picture of an atypical presentation being handled within ordinary protocols. Ambulance crews operate within structured decision-support tools designed for common presentations; those tools are necessarily conservative and rarely anticipate the exotic. The clinical evidence does not suggest indifference. It suggests a system doing what it was built to do, with the information it had.

The more searching line of questioning has concerned the interval between first contact and the point at which the possibility of a deliberate poisoning entered the clinical thinking. That interval is not merely a matter of minutes and hours. It determines when specialist advice is sought, when protective measures are adopted, and when the patient is moved into a different category of care.

Handover as evidence

Handover between ambulance and hospital is one of the least glamorous and most consequential moments in any clinical pathway. It is also, forensically, one of the most revealing, because it is where information is compressed, prioritised and occasionally lost.

The Sturgess Inquiry has examined handover records closely. The questions put to witnesses have tended to probe three things: whether the history given by the crew was recorded accurately; whether the receiving team was told everything the crew knew; and whether the record permits anyone, years later, to reconstruct what was said.

That last point matters for transparency. Contemporaneous records are the only reliable bridge between an event and a later hearing. Where entries are brief, where systems are not interoperable, or where verbal handover carries information that never reaches the written page, the evidential gap is not a matter of suspicion — it is a structural feature of how the NHS records care.

It is worth stating plainly, for readers following the Inquiry's proceedings, that an incomplete record is not the same as poor care. The two are often conflated in public discussion. The clinical evidence permits the first conclusion far more readily than the second.

Protocols and their limits

A recurring theme in the evidence has been the difference between having a protocol and being able to apply it. The UK maintains planning arrangements for chemical incidents, and NHS trusts hold major incident plans that are exercised periodically. Those arrangements assume a degree of prior warning: a known release, a defined location, a recognised agent.

Novichok, as the clinical evidence has illustrated, inverts those assumptions. It presents as something common — nausea, dizziness, confusion, respiratory distress — in a person with no evident connection to a targeted attack. Under those conditions, the protocol is not absent; it simply does not activate.

Witnesses have been asked whether clinicians could reasonably have been expected to consider a nerve agent earlier, and whether the systems in place in 2018 gave them any prompt to do so. The answers have not resolved the question so much as framed it: recognition depends on suspicion, and suspicion depends on information flowing from outside the clinical setting as much as from within it.

Duty of care and the standard applied

The Inquiry is not a criminal trial, and it does not sit to apportion blame. Its function is to establish facts and, where appropriate, to recommend change. That procedural reality shapes how the clinical evidence should be read.

Nevertheless, the evidence engages questions of duty of care in a straightforward sense. Clinicians owe their patients a duty to exercise reasonable skill and care. The standard is not omniscience. The relevant question for the Inquiry has been whether the care provided met that standard given what was known, or could reasonably have been known, at each stage.

The answer emerging from the record appears to be layered. For the individual clinicians involved, the evidence does not readily support a conclusion of departure from accepted practice. For the wider system — the arrangements for information-sharing between police, public health and acute trusts — the picture is less settled, and it is here that the Inquiry's recommendations are most likely to land.

What it means for planning in 2026

Eight years separate the events under examination from this year's public reporting, and the NHS has changed considerably in that interval: new incident response structures, revised chemical hazard guidance, and a markedly different digital estate. The Inquiry's clinical evidence is therefore being tested against a moving target.

Even so, several durable lessons suggest themselves. First, that handover documentation is a public accountability mechanism as much as a clinical one. Second, that recognition of rare agents depends on effective cross-agency communication, not solely on clinical skill. Third, that exercises which assume a known agent test only half the problem.

Whether the Inquiry adopts these points in its final report is a matter for Baroness Hallett and her team. What the record already offers is a detailed, if imperfect, account of how a health system met an event it had no reason to expect — and of the small gaps, in notes and in handovers, through which later scrutiny must work.

The record and its gaps

For readers seeking to follow this strand, the clinical evidence is a reminder that inquests deal in what can be proved, not what is suspected. The value of the Sturgess record lies precisely in its granularity: it shows a system under strain, staff acting in good faith, and documentation that sometimes fell short of what transparency now requires.

A report expected later in 2026 will decide what weight that record carries. Until then, the clinical material remains open to reading — and to scrutiny — by anyone with an interest in how the NHS recognises the unrecognisable.